The authors have disclosed that they have no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors. This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
DeNavas-Walt C, Proctor BD, Smith JC. Income, poverty, and health insurance coverage in the United States: 2012. Current population reports. Available at: https://www.census.gov/prod/2013pubs/p60-245.pdf. Accessed October 12, 2015.
Walker GV, Grant SR, Guadagnolo BA et al.. Disparities in stage at diagnosis, treatment, and survival in nonelderly adult patients with cancer according to insurance status. J Clin Oncol 2014;32:3118–3125.
Ward EM, Fedewa SA, Cokkinides V, Virgo K. The association of insurance and stage at diagnosis among patients aged 55 to 74 years in the national cancer database. Cancer J 2010;16:614–621.
Halpern MT, Ward EM, Pavluck AL et al.. Association of insurance status and ethnicity with cancer stage at diagnosis for 12 cancer sites: a retrospective analysis. Lancet Oncol 2008;9:222–231.
Fedewa SA, Etzioni R, Flanders WD et al.. Association of insurance and race/ethnicity with disease severity among men diagnosed with prostate cancer, National Cancer Database 2004-2006. Cancer Epidemiol Biomarkers Prev 2010;19:2437–2444.
Mahal BA, Aizer AA, Ziehr DR et al.. The association between insurance status and prostate cancer outcomes: implications for the Affordable Care Act. Prostate Cancer Prostatic Dis 2014;17:273–279.
Stephenson AJ, Scardino PT, Eastham JA et al.. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst 2006;98:715–717.
Cooperberg MR, Pasta DJ, Elkin EP et al.. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol 2005;173:1938–1942.
- Search Google Scholar
- Export Citation
. Cooperberg MR Pasta DJ Elkin EP The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol 2005; 173: 1938– 1942.
Klotz L, Zhang L, Lam A et al.. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2009;28:126–131.
Bill-Axelson A, Holmberg L, Garmo H et al.. Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med 2014;370:932–942.
Vickers A, Bennette C, Steineck G et al.. Individualized estimation of the benefit of radical prostatectomy from the Scandinavian Prostate Cancer Group randomized trial. Eur Urol 2012;62:204–209.
Mohler JL, Armstrong AJ, Bahnson RR et al.. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 1, 2015. Available at NCCN.org. Accessed April 01, 2014.
Heidenreich A, Bastian PJ, Bellmunt J et al.. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2014;65:467–479.
Wilt TJ, Brawer MK, Jones KM et al.. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012;367:203–213.
Culp SH, Schellhammer PF, Williams MB. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. Eur Urol 2014;65:1058–1066.
Fossati N, Trinh QD, Sammon J et al.. Identifying optimal candidates for local treatment of the primary tumor among patients diagnosed with metastatic prostate cancer: a SEER-based study. Eur Urol 2015;67:3–6.
Aizer AA, Falit B, Mendu ML et al.. Cancer-specific outcomes among young adults without health insurance. J Clin Oncol 2014;32:2025–2030.
O'Kelly F, Thomas A, Murray D et al.. Can delayed time to referral to a tertiary level urologist with an abnormal PSA level affect subsequent Gleason grade in the opportunistically screened population? Prostate 2013;73:1263–1269.
Dall'era MA, Hosang N, Konety B et al.. Sociodemographic predictors of prostate cancer risk category at diagnosis: unique patterns of significant and insignificant disease. J Urol 2009;181:1622–1627; discussion 1627.
Swan J, Breen N, Coates RJ et al.. Progress in cancer screening practices in the United States: results from the 2000 National Health Interview Survey. Cancer 2003;97:1528–1540.
Moyer VAU.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012;157:120–134.
Carlsson S, Vickers AJ, Roobol M et al.. Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force Review. J Clin Oncol 2012;30:2581–2584.
Wolf AM, Wender RC, Etzioni RB et al.. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin 2010;60:70–98.
Bastian PJ, Boorjian SA, Bossi A et al.. High-risk prostate cancer: from definition to contemporary management. Eur Urol 2012;61:1096–1106.
Aizer AA, Wilhite TJ, Chen MH et al.. Lack of reduction in racial disparities in cancer-specific mortality over a 20-year period. Cancer 2014;120:1532–1539.
Ellimoottil C, Miller DC. Anticipating the effect of the Patient Protection and Affordable Care Act for patients with urologic cancer. Urol Oncol 2014;32:55–58.
Koroukian SM, Bakaki PM, Raghavan D. Survival disparities by Medicaid status: an analysis of 8 cancers. Cancer 2012;118:4271–4279.